Ongoing Phase II Study of Brentuximab Vedotin in Relapsed/Refractory HL: 3-Year Follow-Up and Characterization of Long-Term Remissions


Ongoing Phase II Study of Brentuximab Vedotin in Relapsed/Refractory HL: 3-Year Follow-Up and Characterization of Long-Term Remissions
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Christopher Flowers, MD, MS (2/24/14)
Gopal AK et al. Three-year follow-up data and characterization of long-term remissions from an ongoing Phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Proc ASH 2013;Abstract 4382.

Dr Flowers is Associate Professor of Hematology and Medical Oncology at Emory School of Medicine Winship Cancer Institute in Atlanta, Georgia.